



SZABO SCANDIC

Part of Europa Biosite

Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!
See the following pages for more information!



Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

mail@szabo-scandic.com

www.szabo-scandic.com

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

Acatamab

Cat. No.:	HY-P99418
CAS No.:	2314491-93-3
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.

BIOLOGICAL ACTIVITY

Description	Acatamab (AMG-160) is an anti-CD3E/FOLH1 monoclonal antibody ^[1] .									
IC₅₀ & Target	CD3E/FOLH1									
In Vitro	<p>Acatamab (AMG-160; 0-10000 pM; 48 h) induces T-cell activation and increases in CD25, CD69, 4-1BB, and PD-1 expression on T cells^[1].</p> <p>Acatamab (0-10000 pM; 48 h; T-cell) induces dose-dependent secretion of cytokines, including IL2, IL4, IL6, IL10, IFNγ, and TNFα^[1].</p> <p>Acatamab (0-10000 pM; 48 h) induces potent lysis of prostate-specific membrane antigen (PSMA)-positive prostate cancer cell lines in cocultures with PBMC, with EC₅₀ values of 6-42 pM^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p>									
In Vivo	<p>Acatamab (0.02-2 mg/kg; i.v.; days 16, 23, and 31) has antitumor activity and inhibits tumor growth in NOD/SCID mice with 22Rv-1 CRPC xenografts^[1].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" data-bbox="324 1344 1510 1596"> <tr> <td>Animal Model:</td> <td>NOD/SCID mice with 22Rv-1 CRPC xenografts^[1]</td> </tr> <tr> <td>Dosage:</td> <td>0.02, 0.2, and 2 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intravenous injection (days 16, 23, and 31)</td> </tr> <tr> <td>Result:</td> <td>Had antitumor activity against established CRPC tumors.</td> </tr> </table>		Animal Model:	NOD/SCID mice with 22Rv-1 CRPC xenografts ^[1]	Dosage:	0.02, 0.2, and 2 mg/kg	Administration:	Intravenous injection (days 16, 23, and 31)	Result:	Had antitumor activity against established CRPC tumors.
Animal Model:	NOD/SCID mice with 22Rv-1 CRPC xenografts ^[1]									
Dosage:	0.02, 0.2, and 2 mg/kg									
Administration:	Intravenous injection (days 16, 23, and 31)									
Result:	Had antitumor activity against established CRPC tumors.									

REFERENCES

[1]. Acatamab

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA